Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Public ClinicalTrials.gov record NCT05218499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma
Study identification
- NCT ID
- NCT05218499
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Brigimadlin Drug
- Doxorubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2022
- Primary completion
- Apr 15, 2024
- Completion
- Jan 25, 2026
- Last update posted
- Mar 1, 2026
2022 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Arizona | Tucson | Arizona | 85719 | — |
| Precision NextGen Oncology | Beverly Hills | California | 90212 | — |
| City of Hope-Duarte-56419 | Duarte | California | 91010 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| Mayo Clinic Cancer Center | Jacksonville | Florida | 32224 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic, Rochester | Rochester | Minnesota | 55905 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists-Omaha-69502 | Omaha | Nebraska | 68114 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Oregon Health and Sciences University | Portland | Oregon | 97239 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Froedtert and The Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05218499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05218499 live on ClinicalTrials.gov.